Arti Hurria1, Enrique Soto-Perez-de-Celis1,2, Jacob B Allred3, Harvey Jay Cohen4, Anait Arsenyan1, Karla Ballman5, Jennifer Le-Rademacher6, Aminah Jatoi3, Julie Filo1, Jeanne Mandelblatt7, Jacqueline M Lafky3, Gretchen Kimmick4, Heidi D Klepin8, Rachel A Freedman9, Harold Burstein9, Julie Gralow10, Antonio C Wolff11, Gustav Magrinat12, Myra Barginear13, Hyman Muss14. 1. City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, California. 2. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico. 3. Mayo Clinic, Rochester, Minnesota. 4. Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina. 5. Weill Medical College, Cornell University, New York, New York. 6. Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota. 7. MedStar Georgetown University Hospital, Washington, District of Columbia. 8. Wake Forest University Health Sciences, Winston Salem, North Carolina. 9. Dana-Farber Cancer Institute, Boston, Massachusetts. 10. University of Washington Seattle Cancer Care Alliance, Seattle, Washington. 11. Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland. 12. Cone Health Cancer Center, Greensboro, North Carolina. 13. Northwell Health-North Shore Long Island Jewish Medical Center, New Hyde Park, New York. 14. University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina.
Abstract
OBJECTIVES: To analyze self-reported changes in physical function in older women with breast cancer receiving adjuvant chemotherapy. DESIGN: Secondary analysis of the Cancer and Leukemia Group B (CALGB) 49907 prospective randomized clinical trial. SETTING: CALGB institutions in the United States. PARTICIPANTS: Women aged 65 and older with Stage I to III breast cancer enrolled in CALGB 49907 who had physical function data from before and after receipt of adjuvant chemotherapy (N=256; mean age 71.5, range 65-85). MEASUREMENTS: Participants were administered the physical function subscale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire before chemotherapy, at the end of chemotherapy, and 12 months after chemotherapy initiation. Functional decline was defined as a more than 10-point decrease from baseline at each time point. Resilience was defined as return to within 10 points of baseline. Multivariable regression was used to examine pretreatment characteristics associated with physical function changes. RESULTS: Of 42% of participants who had physical function decline from before to the end of chemotherapy, 47% recovered by 12 months (were resilient). Almost one-third experienced functional decline from before chemotherapy to 12 months later. Pretreatment fatigue was a risk factor for functional decline from before to the end of chemotherapy (P=.02). Risk factors for functional decline at 12 months included pretreatment dyspnea (P=.007) and being unmarried (P=.01). CONCLUSION:Functional decline was common in older women receiving adjuvant chemotherapy for breast cancer in a clinical trial. Although half recovered their physical function, one-third had a clinically meaningful decline at 12 months. Strategies are needed to prevent functional decline in older adults receiving chemotherapy. J Am Geriatr Soc 67:920-927, 2019.
RCT Entities:
OBJECTIVES: To analyze self-reported changes in physical function in older women with breast cancer receiving adjuvant chemotherapy. DESIGN: Secondary analysis of the Cancer and Leukemia Group B (CALGB) 49907 prospective randomized clinical trial. SETTING: CALGB institutions in the United States. PARTICIPANTS: Women aged 65 and older with Stage I to III breast cancer enrolled in CALGB 49907 who had physical function data from before and after receipt of adjuvant chemotherapy (N=256; mean age 71.5, range 65-85). MEASUREMENTS: Participants were administered the physical function subscale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire before chemotherapy, at the end of chemotherapy, and 12 months after chemotherapy initiation. Functional decline was defined as a more than 10-point decrease from baseline at each time point. Resilience was defined as return to within 10 points of baseline. Multivariable regression was used to examine pretreatment characteristics associated with physical function changes. RESULTS: Of 42% of participants who had physical function decline from before to the end of chemotherapy, 47% recovered by 12 months (were resilient). Almost one-third experienced functional decline from before chemotherapy to 12 months later. Pretreatment fatigue was a risk factor for functional decline from before to the end of chemotherapy (P=.02). Risk factors for functional decline at 12 months included pretreatment dyspnea (P=.007) and being unmarried (P=.01). CONCLUSION: Functional decline was common in older women receiving adjuvant chemotherapy for breast cancer in a clinical trial. Although half recovered their physical function, one-third had a clinically meaningful decline at 12 months. Strategies are needed to prevent functional decline in older adults receiving chemotherapy. J Am Geriatr Soc 67:920-927, 2019.
Authors: Candyce H Kroenke; Laura D Kubzansky; Eva S Schernhammer; Michelle D Holmes; Ichiro Kawachi Journal: J Clin Oncol Date: 2006-03-01 Impact factor: 44.544
Authors: Wendy Demark-Wahnefried; Elizabeth C Clipp; Miriam C Morey; Carl F Pieper; Richard Sloane; Denise Clutter Snyder; Harvey J Cohen Journal: J Clin Oncol Date: 2006-07-20 Impact factor: 44.544
Authors: Cynthia M Boyd; Michelle Ricks; Linda P Fried; Jack M Guralnik; Qian-Li Xue; Jin Xia; Karen Bandeen-Roche Journal: J Am Geriatr Soc Date: 2009-08-20 Impact factor: 5.562
Authors: Hyman B Muss; Donald A Berry; Constance T Cirrincione; Maria Theodoulou; Ann M Mauer; Alice B Kornblith; Ann H Partridge; Lynn G Dressler; Harvey J Cohen; Heather P Becker; Patricia A Kartcheske; Judith D Wheeler; Edith A Perez; Antonio C Wolff; Julie R Gralow; Harold J Burstein; Ahmad A Mahmood; Gustav Magrinat; Gutav Magrinat; Barbara A Parker; Ronald D Hart; Debjani Grenier; Larry Norton; Clifford A Hudis; Eric P Winer Journal: N Engl J Med Date: 2009-05-14 Impact factor: 91.245
Authors: Araba Adjei; Jan C Buckner; Elizabeth Cathcart-Rake; Hongbin Chen; Harvey J Cohen; Dyda Dao; Jo-Ellen De Luca; Josephine Feliciano; Rachel A Freedman; Richard M Goldberg; Judith Hopkins; Joleen Hubbard; Aminah Jatoi; Meghan Karuturi; Margaret Kemeny; Gretchen G Kimmick; Heidi D Klepin; Jessica L Krok-Schoen; Jacqueline M Lafky; Jennifer G Le-Rademacher; Daneng Li; Stuart M Lichtman; Ronald Maggiore; Jeanne Mandelblatt; Vicki A Morrison; Hyman B Muss; Michael O Ojelabi; Mina S Sedrak; Niveditha Subbiah; Virginia Sun; Susan Tuttle; Noam VanderWalde; Tanya Wildes; Melisa L Wong; Jennifer Woyach Journal: J Geriatr Oncol Date: 2019-06-11 Impact factor: 3.599
Authors: Clark DuMontier; Mina S Sedrak; Wee Kheng Soo; Cindy Kenis; Grant R Williams; Kristen Haase; Magnus Harneshaug; Hira Mian; Kah Poh Loh; Siri Rostoft; William Dale; Harvey Jay Cohen Journal: J Geriatr Oncol Date: 2019-08-23 Impact factor: 3.599
Authors: Hyman B Muss; Mei-Yin C Polley; Donald A Berry; Heshan Liu; Constance T Cirrincione; Maria Theodoulou; Ann M Mauer; Alice B Kornblith; Ann H Partridge; Lynn G Dressler; Harvey J Cohen; Patricia A Kartcheske; Edith A Perez; Antonio C Wolff; Julie R Gralow; Harold J Burstein; Ahmad A Mahmood; Linda M Sutton; Gustav Magrinat; Barbara A Parker; Ronald D Hart; Debjani Grenier; Arti Hurria; Aminah Jatoi; Larry Norton; Clifford A Hudis; Eric P Winer; Lisa Carey Journal: J Clin Oncol Date: 2019-07-24 Impact factor: 44.544
Authors: Nita H Mukand; Naomi Y Ko; Nadia A Nabulsi; Colin C Hubbard; Brian C-H Chiu; Kent F Hoskins; Gregory S Calip Journal: Breast Cancer Date: 2021-11-19 Impact factor: 4.239
Authors: Brent J Small; Marie Lange; Jeanne Mandelblatt; Florence Joly; Wanting Zhai; Jaeil Ahn; Tim A Ahles; Judith E Carroll; Harvey J Cohen; Deena Graham; Martine Extermann; Natacha Heutte; Heather S L Jim; Brenna C McDonald; Sunita K Patel; James C Root; Andrew J Saykin; Kathleen Van Dyk; Xingtao Zhou Journal: Breast Cancer Res Treat Date: 2021-11-24 Impact factor: 4.872
Authors: Cynthia Owusu; Nora L Nock; Paul Hergenroeder; Kristina Austin; Elizabeth Bennet; Stephen Cerne; Halle Moore; Jean Petkac; Mark Schluchter; Kathryn H Schmitz; Monica Webb Hooper; Lindsay Atkins; Oghenerukeme Asagba; Leonard Wimbley; Nathan A Berger Journal: Contemp Clin Trials Date: 2020-04-15 Impact factor: 2.226
Authors: Lindsay C Kobayashi; Harvey Jay Cohen; Wanting Zhai; Xingtao Zhou; Brent J Small; George Luta; Arti Hurria; Judith Carroll; Danielle Tometich; Brenna C McDonald; Deena Graham; Heather S L Jim; Paul Jacobsen; James C Root; Andrew J Saykin; Tim A Ahles; Jeanne Mandelblatt Journal: Psychooncology Date: 2020-03-17 Impact factor: 3.894
Authors: Tim A Ahles; Elizabeth Schofield; Yuelin Li; Elizabeth Ryan; James C Root; Sunita K Patel; Katrazyna McNeal; Alexandra Gaynor; Heidi Tan; Vani Katheria; Jessica Vazquez; Tiffany Traina; Arti Hurria Journal: J Geriatr Oncol Date: 2021-08-05 Impact factor: 3.929